Teva to cut jobs at its Runcorn manufacturing site

Teva to identify redeployment opportunities as part of its plan to make 60 redundancies at its Runcorn branch, according to the Liverpool Echo

The redundancy announcement was made to the Teva workforce as part of a long-term plan to “ensure the future sustainability of the site in an increasingly competitive global environment for the production of complex pharmaceutical products”, according to the news site.

It added Teva’s plans are aimed at securing the future success of the site and maintaining its commitment to manufacturing in Runcorn.

Tevaa said: “The transformation we are undertaking requires investment in the skills and capabilities of our employees on the Runcorn site, building their technical expertise, and increasing the number of specialist roles in order to support the greater use of technology and automation now required in complex drug process development and manufacture.

“As part of this planning for the future, Teva last week announced consultation on a restructure aimed at delivering a broadening of the skills of the majority of employees, but alongside this the loss of a number of roles from the current organisation.”

The company added: “The proposed restructure would involve the potential loss of around 80 positions, and the creation of approximately 20 new specialist roles reflecting the overall upskilling of the site.

“We will give all Teva employees the fullest support through the forthcoming period of change.”